Insurance Called My Treatment Experimental — How to Fight That

Your doctor recommended a specific treatment. Maybe it's a newer therapy, a drug used in a non-standard way, a procedure that's gaining acceptance in the medical community, or a treatment option that's cutting-edge but increasingly recognized as effective. And your insurance company has responded by stamping it "experimental" or "investigational" — and denying your claim.

This label is one of the most infuriating — and most commonly misapplied — denial reasons in the insurance world.

Here's the reality: what insurance companies call "experimental" often has substantial clinical evidence behind it. Insurers apply this label based on their own proprietary clinical criteria, which frequently lag behind actual medical science and standards of care. And these denials are successfully challenged every day.

What "Experimental" Actually Means (According to Insurers)

Most insurance plans define experimental or investigational treatment as care that:

• Lacks sufficient evidence of clinical effectiveness
• Is not generally accepted by the medical community
• Is not approved by the FDA for the specific use
• Is subject to ongoing clinical investigation

The problem is that insurance companies apply these criteria inconsistently, with criteria that haven't been updated to reflect recent medical advances, and without the specialist-level expertise to evaluate emerging treatments in complex fields like oncology, neurology, or rare disease medicine.

Your oncologist may know that a specific targeted therapy is the standard of care for your mutation profile. Your insurer's clinical reviewer, using outdated criteria, may still call it investigational.

The Most Common "Experimental" Denial Scenarios

Off-label drug use: Your doctor prescribed an FDA-approved drug for a condition it wasn't specifically approved to treat. Roughly 20% of all cancer prescriptions are off-label — this is normal medical practice. Insurers frequently deny them as "experimental" even when they're widely used and evidence-based.

Newer surgical or procedural techniques: A surgical approach that's become the surgical community's preferred method hasn't been formally added to the insurer's coverage criteria yet.

Emerging cancer immunotherapies and targeted therapies: The field of oncology moves faster than most insurer coverage criteria update cycles. Checkpoint inhibitors, targeted therapies, and CAR-T cell therapies have revolutionized cancer treatment — but some insurers still deny them as investigational.

Genetic testing: Genetic testing to guide cancer treatment or identify inherited conditions is increasingly standard of care but is frequently labeled experimental by some plans.

Novel treatments for rare diseases: When a disease is rare, there may be fewer large clinical trials, but the available evidence may strongly support a treatment. Insurers sometimes exploit the limited trial data to call a treatment investigational.

How to Fight an Experimental Treatment Denial

Step 1: Get the insurer's clinical criteria for the denial

Request in writing the specific clinical criteria and evidence standards the insurer used to classify your treatment as experimental. Under federal law, you're entitled to this.

Review these criteria carefully. Often you'll find they reference outdated guidelines or haven't been updated to reflect current medical consensus.

Step 2: Mobilize your specialist

Your treating physician — especially if they're a specialist in your condition — is your primary weapon. Ask them to write a detailed letter that:

• Explains why this treatment is not experimental, but rather the current standard of care for your specific situation
• Cites peer-reviewed clinical literature demonstrating the treatment's effectiveness
• References clinical practice guidelines from major medical societies supporting the treatment (NCCN for cancer, AAN for neurology, ACC for cardiology, etc.)
• Documents the FDA approval status and, for off-label use, the specific evidence supporting that use
• If applicable, documents that this treatment is covered by other major insurers or is included in Medicare coverage policies

This letter should be detailed and clinically specific. The more it reads like a journal article and less like a form letter, the better.

Step 3: Research clinical trial status and guideline inclusion

Many treatments labeled experimental by insurers are:

• Included as recommended treatment options in major clinical society guidelines
• Covered by Medicare (which has its own evidence-based coverage determinations)
• Included as standard care in clinical trial protocols at major academic medical centers
• Supported by multiple published clinical trials even if not in a single randomized controlled trial

Document all of this for your appeal.

Step 4: Address the FDA approval question directly

For off-label drug use specifically: cite the off-label use protections in many state laws and the Medicare rules regarding coverage of off-label drug use for conditions supported in major clinical compendia (NCCN compendium, Micromedex, etc.). Many states require insurers to cover off-label uses listed in major compendia.

Step 5: File your formal appeal

Your appeal should:

• Directly dispute the "experimental/investigational" characterization with specific evidence
• Cite guidelines and literature supporting the treatment
• Reference your insurer's own criteria and show how the treatment meets them (or argue the criteria are outdated)
• Include your doctor's letter, copies of relevant guidelines, and key research summaries

Step 6: External Independent Review: Complete Guide" class="auto-link">External review is especially powerful here

External reviewers — independent medical professionals — frequently disagree with experimental/investigational designations when the clinical evidence is strong. They evaluate the evidence without the same institutional conservatism that affects in-house insurer reviewers.

If your internal appeal fails, file for external review immediately. For cancer treatments and other serious conditions, external reversal rates for these denials are significant.

State Protections for Clinical Trials

Many states have laws requiring insurers to cover the routine care costs for patients enrolled in qualifying clinical trials. If your denied treatment is part of a clinical trial, research your state's clinical trial participation protections.

Persistence Is the Key

Experimental treatment denials often take multiple rounds of escalation. Don't give up after the first appeal. Bring in additional specialist opinions. Update your clinical evidence package as new research is published. Escalate through every available level.

Patients who persist win these battles.

Fight Back With ClaimBack

ClaimBack helps patients fight experimental treatment denials with evidence-based appeal packages that challenge insurer clinical criteria directly.

Start your appeal at https://claimback.app/appeal

Your treatment isn't experimental. Prove it — and make them pay for it.

Related Reading

• What Is Medical Necessity and How Does It Affect Your Claim?
• Internal vs. External Insurance Appeal: Which Should You File?
• How to Write an Insurance Appeal Letter